The signal transducer and activator of transcription (Stat) family of molecules play important roles in a variety of cytokine-mediated cellular responses, including cell growth, survival, differentiation and function, by conveying signals from cytokine receptors to the nucleus and regulating cytokine-inducible gene expression. [1] [2] [3] To date, seven mammalian Stat family members have been identified, including Stat1, 2, 3, 4, 5A, 5B, and 6 and each Stat member has unique functions in cytokine signaling. and IL-5-driven differentiation of Th2-type eosinophils.
Introduction
The signal transducer and activator of transcription (Stat) family of molecules play important roles in a variety of cytokine-mediated cellular responses, including cell growth, survival, differentiation and function, by conveying signals from cytokine receptors to the nucleus and regulating cytokine-inducible gene expression. [1] [2] [3] To date, seven mammalian Stat family members have been identified, including Stat1, 2, 3, 4, 5A, 5B, and 6 and each Stat member has unique functions in cytokine signaling. 3 The two closely related Stat5 proteins (Stat5A and Stat5B) have been of particular interest because of the broad spectrum of hematopoietic cytokines and growth factors that induce their activation. 3 Gene disruptions in mice have highlighted important functions for Stat5 proteins. Stat5A deficiency disrupts prolactin-mediated functions in the lactating mammary gland 4, 5 whereas Stat5B deficiency blocks growth hormone-regulated functions in the liver. 5, 6 Studies of Stat5A/5B nullizygous mice have illustrated key roles for Stat5A and Stat5B in prolactin-regulated ovarian function, 5 repopulating potential of hematopoietic stem cells, 7, 8 IL-2-induced T cell proliferation, 9 IL-3-mediated mast cell development and survival, 10 and IL-5-driven differentiation of Th2-type eosinophils.
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Stat5 proteins, as other Stat members, exist normally as latent monomers in the cytoplasm and activation of Stat5 is totally dependent upon phosphorylation of a single tyrosine residue by Janus family of protein tyrosine kinases (Jaks). 1, 2 Upon cytokine binding, cytokine receptors aggregate and activate one or more members of the Jaks.
Activated Jaks phosphorylate Stat5 proteins, which in turn dimerize, translocate to the nucleus and activate transcription of a variety of genes. [1] [2] [3] Activation of Stat5 is modulated in both magnitude and duration, such that normal function of Stat5 requires its For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From proper activation and inactivation. Constitutive activation of Stat5 is frequently found in leukemic cells derived from BCR-ABL-induced chronic myelogenous and lymphogenous leukemia. [12] [13] [14] [15] A constitutively active Stat5A mutant is able to transform growth factordependent cells to growth factor independence, 16 to induce a rapidly fatal myeloproliferative disease in mice, 17 and to lead to an abnormal increase in numbers of T and B cells. 18 Although much is known about Stat5 activation, the mechanism by which it is inactivated is not fully understood. Our recent studies have identified Shp-2, an SH2 domain-containing protein-tyrosine phosphatase, as a specific Stat5A phosphatase that dephosphorylates active Stat5A. 19 Nonetheless, Shp-2 deficiency only delays dephosphorylation of Stat5A in the cytoplasm and has no effect on the down-regulation of active Stat5A in the nucleus. 19 These observations suggest that additional phosphatases or alternative mechanisms to that of dephosphorylation are involved in turnover of Stat5.
Previous studies have shown that proteasome inhibitors can dramatically stabilize tyrosine-phosphorylated Stat5. 20 However, there is no direct evidence to support a role for the proteasome in down-regulation of active Stat5.
In the current studies, we demonstrate that the mechanism involved in downregulation of tyrosine-phosphorylated Stat5A in the nucleus differs from that in the cytoplasm, and exclusively depends on proteasome-mediated protein degradation instead of phosphatase-mediated dephosphorylation.
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Materials and methods

Antibodies, cDNAs, and inhibitors
Anti-phosphoStat5 monoclonal (30979345, ZYMED Laboratories), anti-Stat5 monoclonal (610191, BD Biosciences), anti-Stat5A polyclonal (as previously described 20 ), anti-Flag monoclonal (M2, Sigma-Aldrich), anti-G-6-PDH polyclonal (A9521, Sigma-Aldrich), anti-HA monoclonal (12CA5, Abcam), anti-p53 monoclonal (Ab7, Calbiochem), anti-YY1 monoclonal (sc-7341, Santa Cruz Biotechnology), antihuman Ubc5 polyclonal (A-615, Boston Biochem), and anti-ubiquitin polyclonal 21 antibodies were used for immunoprecipitation or Western blot analyses. The cDNAs encoding murine JAK2 and Stat5A were as previously described 20 and cDNAs encoding HA-tagged wild-type ubiquitin, K48R ubiquitin, and K63R ubiquitin in mammalian expression vector pEF were kindly provided by Dr. Zhijian Chen (University of Texas Southwestern Medical Center, TX, USA). The proteasome inhibitor MG132 was purchased from Peptide Institute, Inc. and the nuclear export inhibitor Leptomycin B and protease inhibitors NEM, TLCK, and TPCK were purchased from Sigma-Aldrich.
Cell culture and transfection
32D (EpoR wt) cells were cultured in RPMI-1640 containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin and supplemented with murine IL-3 (20 units/ml). Human Ubc5b was introduced into 32D (EpoR wt) cells via retrovirusmediated gene transfer as previously described. 22 Briefly, the human Ubc5b gene was cloned into a bicistronic retrovirus MSCV-IRES-GFP vector. The expression of the cloned gene and GFP is under murine stem cell virus (MSCV) promoter control. Conditioned media containing high-titer, amphotropic retrovirus particles were derived by cotransfection of 293T cells with the retrovirus vector expressing the cloned gene and GFP and a helper plasmid pEQPAM3 containing the required gag, pol, and env retroviral genes. This media was used to transduce 32D (EpoR wt) cells with 6 µg/ml polybrene (Sigma). Cells exhibiting high GFP expression were sorted and subsequently expanded as Ubc5b over-expressing cells.
COS-7 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. For transfection in COS-7 cells, various combinations of cDNAs in mammalian expression vectors were transfected into COS-7 cells using LipoFectamine (Invitrogen) according to the manufacturer's instructions. Cells were lysed in lysis buffer (10 mM HEPES, pH 7.9, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, aprotinin 3 Kg/ml, pepstain 2 Kg/ml, leupeptin 1 Kg/ml, 5mM NEM, 0.25mM TPCK, 0.25mM TLCK) for analysis 48 h after transfection.
RT-PCR
Total RNA was prepared from the cells using RNAzol B (Tel-Test). First-strand cDNA was synthesized from total RNA with the Gene Amp RT-PCR kit (Perkin-Elmer) and subjected to semi-quantitative PCR analysis. The specific primers for Stat5 target gene CIS were as follows: 5' primer, TGGAGCAGCTGTTGATGGACCTAC; 3' primer, AGATGATGCTTTGACAGAAGGCTATC. The -actin gene was used as an internal RNA level control and the specific primers for -actin were: 5' primer, ACTCCTATGTGGGTGACGAG; 3' primer, CAGGTCCAGACGCAGGATGGC.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From Preparation of cytoplasmic and nuclear extracts 32D (EpoR wt) cells were starved overnight and pre-treated with or without LMB (5 ng/mL) for 60 min or MG132 (40 KM) for 30 min, followed by stimulation with IL-3 for 15 min. After removal of the cytokine, the cells were continually cultured in the presence or absence of LMB or MG132 as indicated. At the indicated time points, cells (2 x 10   7   ) were collected and suspended in 100 Kl of cold buffer A (10 mM HEPES, pH7.9, 10 mM KCl, 0.2 mM EDTA, 1 mM DTT, 3 Kg/ml aprotinin, 2 Kg/ml pepstain, 1 Kg/ml leupeptin). After incubation on ice for 15 min, NP-40 was added to a final concentration of 0.5%. The mixtures were vortexed for 10 sec and spun at 13,000 rpm for 30 sec. The supernatants were collected as the cytoplasmic extracts. The pellets were washed with Buffer A once and resuspended in 50 Kl of buffer B (20 mM HEPES pH 7.9, 400 mM NaCl, 2 mM EDTA, 1 mM DTT, 3 Kg/ml aprotinin, 2 Kg/ml pepstain, 1 Kg/ml leupeptin), followed by incubation on ice for 15 min. The mixtures were spun at 13,000 rpm for 5 min and the supernatants were collected as the nuclear extracts. In ubiquitination assays, the protease inhibitors NEM, TPCK and TLCK were added to both the cytoplasmic and nuclear extracts.
Oligodeoxynucleotides pull-down
The Stat5 optimal DNA binding sequences were determined using STAT homodimers in binding and amplification reactions with random oligodeoxynucleotides as previously described. 2 The oligodeoxynucleotides containing optimal Stat5-binding sequences (sense 5'-GATCCGAATTCCAGGAATTC A-3' and anti-sense 3'-GCTTAAGGTCCTTAAGTCTAG-5') were synthesized, conjugated to biotin and ) were lysed in lysis buffer (10mM HEPES, pH7.9, 150 mM NaCl, 1 mM EDTA, 0.5%NP-40, aprotinin 3 Kg/ml, pepstain 2 Kg/ml, leupeptin 1 Kg/ml) at 4 °C. The cytoplasmic or nuclear extracts were pre-cleared with Sepharose beads. Subsequently, the extracts were incubated with 5 Kl of the biotin-labeled double stranded oligodeoxynucleotides (20 Kg/ml) at 4 °C for 30 min, followed by incubation with avidin-conjugated Sepharose beads at 4 °C for 2 h. After washing three times with cold lysis buffer, the proteins bound to the avidin-conjugated Sepharose beads were subjected to SDS-PAGE and Western blot analysis.
In vitro ubiquitination assay
Ubiquitin was purchased from Sigma-Aldrich, purified to apparent homogeneity and radioiodinated by the chloramine-T procedure to obtain 125 I-ubiquitin. 23 Human erythrocyte E1 enzyme and various recombinant E2s were purified to apparent homogeneity and functionally assayed as previously described. 24 Active Stat5 proteins were pulled down from nuclear extracts or total cell lysates using Stat5-binding Previous studies identified Shp-2 as a Stat5A phosphatase that specifically dephosphorylates tyrosine-phosphorylated Stat5A in the cytoplasm. 19, 25 However, in the absence of Shp-2, down-regulation of tyrosine-phosphorylated Stat5A that had translocated into the nucleus proceeded normally. 19 Thus, the mechanism by which nuclear tyrosine-phosphorylated Stat5A is inactivated is unclear. To determine the inactivation mechanism of nuclear active Stat5A, we examined down-regulation of tyrosine-phosphorylated Stat5A in 32D (EpoR wt) cells, an IL-3-dependent myeloid cell line that also expresses wild-type erythropoietin receptors (EpoR wt). 32D (EpoR wt) cells were starved and stimulated with IL-3. At different time points following removal of IL-3, cytoplasmic and nuclear extracts were prepared and levels of tyrosinephosphorylated and total Stat5A protein in the extracts were assessed by direct Western blot analysis. In the cytoplasm, tyrosine-phosphorylated Stat5A disappeared 2 hrs after removal of the cytokine whereas the amount of total Stat5A remained constant throughout the duration of the experiment ( Figure 1A ). In contrast, nuclear tyrosinephosphorylated Stat5A and total Stat5A protein levels disappeared 2 hrs after cytokine removal of ( Figure 1A) . Therefore, inactivation of cytoplasmic tyrosine-phosphorylated Stat5A is mainly through dephosphorylation, consistent with the previous findings that Shp-2 specifically dephosphorylates Stat5A in the cytoplasm, 19 whereas a different mechanism is involved in the down-regulation of nuclear tyrosine-phosphorylated
Stat5A.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From Based on the disappearance of total Stat5A proteins in the nucleus, downregulation of nuclear active Stat5A could arise by export to the cytoplasm, protein degradation, or both. To distinguish between the two possibilities, we first examined the effect of Leptomycin B (LMB), a specific inhibitor of nuclear export, [26] [27] [28] on the turnover of nuclear Stat5A proteins. LMB binds to the receptor for the nuclear export signal (NES), named chromosome region maintenance 1 (CRM1/exportin 1), and inhibits nuclear export. [26] [27] [28] Studies have shown that LMB is able to block nuclear export of Stat proteins. [29] [30] [31] [32] Starved 32D (EpoR wt) cells were pre-treated with LMB, followed by stimulation with IL-3. After removal of the cytokine, levels of tyrosine-phosphorylated Stat5A and the amount of total Stat5A proteins in cytoplasmic and nuclear extracts were assessed. The rates of disappearance for both tyrosine-phosphorylated and total Stat5A proteins in the nucleus were comparable in the presence and absence of LMB ( Figure 1A , left). In addition, LMB had no effect on the down-regulation of cytoplasmic tyrosinephosphorylated Stat5A or on the constant level of total cytoplasmic Stat5A proteins ( Figure 1A , right). As a control, LMB blocked nuclear export of p53, resulting in nuclear accumulation, as reported previously 33 ( Figure 1B ). Therefore, these data preclude export as the mechanism for turnover of Stat5A proteins in the nucleus.
Our previous studies have shown that the MG132 proteasome inhibitor stabilizes tyrosine-phosphorylated Stat5A in total cell lysates, 20 suggesting that protein degradation might be involved in the down-regulation of tyrosine-phosphorylated Stat5A. Next, we examined the effect of MG132 on the down-regulation of nuclear and cytoplasmic tyrosine-phosphorylated Stat5A. Starved 32D (EpoR wt) cells were pre-treated with MG132, followed by stimulation with IL-3. At different time points after cytokine removal, nuclear and cytoplasmic levels of tyrosine-phosphorylated and total Stat5A protein pools were assessed. In the nucleus, MG132 completely stabilized tyrosinephosphorylated Stat5A as well as total Stat5A proteins (Figure 2 , left). In contrast, in the cytoplasm, MG132 only partially stabilized tyrosine-phosphorylated Stat5A (Figure 2 , right), consistent with the notion that Shp-2 dephosphorylates Stat5 in the cytoplasm. 19 These data indicate that proteasome-mediated protein degradation might regulate the turnover of tyrosine-phosphorylated Stat5A in a subcellular compartment-specific manner.
Ubiquitination of Stat5A in the nucleus
Although proteasome inhibitors stabilize the nuclear tyrosine-phosphorylated Stat5A, it is not clear whether proteasome-mediated protein degradation is directly or indirectly For personal use only. on April 14, 2017. by guest www.bloodjournal.org From
K48-linked poly-ubiquitination of Stat5A
The type of ubiquitin linkage determines the fate of ubiquitinated proteins. K48-linked ubiquitination generally directs proteins to the proteasome for degradation whereas K63-linked ubiquitination usually alters protein function or protein-protein interactions. 35 To determine which kind of ubiquitin linkage is involved in the ubiquitination of Stat5, we examined the ability of HA-tagged wild-type ubiquitin (WT) or ubiquitin mutants, in which K48 or K63 was substituted with R (K48R or K63R, repectively) ( Figure 4A ), to ubiquitinate Stat5A. Stat5A and Jak2 kinase were co-transfected with WT, K48R or K63R ubiquitin into COS-7 cells. After transfection, the cells were lysed and the cell lysates were incubated with biotin-labeled Stat5-binding oligodeoxynucleotides and avidin-conjugated Sepharose beads. The bound proteins were subjected to Western blot analysis with antibodies against HA. The tyrosine-phosphorylated Stat5A proteins by Jak2 were pulled down by the Stat5-binding oligos and ubiquitinated by WT and K63R, but not K48R, ubiquitin ( Figure 4B ). These data demonstrate that tyrosinephosphorylated Stat5A can be ubiquitinated and that the poly-ubiquitination of Stat5A is via the K48 linkage, a type that leads to protein degradation. This observation is consistent with the ability of MG132 to stabilize nuclear Stat5A.
Ubiquitination of Stat5A in a cell-free system and identification of Ubc5 as the conjugating enzyme (E2) for Stat5A ubiquitination
To further confirm the ubiquitination of Stat5A and to identify the enzyme(s) involved in Stat5A ubiquitination, we examined the ubiquitination of Stat5A in a cell free system.
Ubiquitination requires the sequential action of three enzymes, including an activating
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From enzyme (E1) that activates ubiquitin, a conjugating enzyme (E2) that transiently carries the activated ubiquitin, and a ligase (E3) that transfers the activated ubiquitin from the E2 to the substrate. 36 There is a single E1, a limited number of E2s, and a larger number of E3s in the entire ubiquitination system. [37] [38] [39] Each E2 serves several E3s and each E3 specifically recognizes a set of substrates. [37] [38] [39] We detected ubiquitination of tyrosinephosphorylated Stat5A in the nucleus of 32D (EpoR wt) cells. We believed that nuclear active Stat5A should form a complex with its E3 ligase. Therefore, we pulled down the 40 . Taken together, these data demonstrate that nuclear tyrosinephosphorylated Stat5A can be ubiquitinated in a cell-free system and Ubc5 is the conjugating E2 for Stat5A ubiquitination.
Lastly, we examined whether overexpression of Ubc5 could affect activation of Stat5A and subsequent expression of its target genes. Although 32D (EpoR wt) cells had easily detectable levels of endogenous Ubc5, introduction of human Ubc5b further elevated levels of Ubc5 in these cells ( Figure 6A ). Nonetheless, overexpression of Ubc5b failed to affect IL-3-induced Stat5A activation ( Figure 6B ), down-regulation of Stat5A upon removal of IL-3 ( Figure 6C ), or induction of Stat5 target gene CIS ( Figure 6D 
findings that elevation of Ubc5 proteins over endogenous levels has no detectable effect on proteasome-mediated degradation of Stat5A suggest either that endogenous levels of Ubc5 proteins already saturate a rate-limiting amount of E2 or that E2 is not the ratelimiting factor for proteasome-mediated degradation of Stat5A. Since ubiquitination of Stat5A mainly occurs in nucleus ( Figure 3) and non-phosphorylated Stat5A monomers cannot enter nucleus, it is reasonable to hypothesize that phosphorylation of Stat5A is required for its ubiquitination. Nonetheless, we further examined whether phosphorylation by itself is required for ubiquitination.
Phosphorylation of
Immunoprecipitation of non-phosphorylated Stat5A by anti-Stat5A antibodies, followed by in vitro ubiquitination assay and Western blot with anti-ubiquitin antibodies, generated high background, which prevented us from detection of ubiquitination of Stat5A. The biotin-labeled double-stranded Stat5-binding oligodeoxynucleotides could reduce the high background and enabled us to detect ubiquitination of tyrosine-phosphorylated Stat5A (Figure 3 ), but could not pull down non-phosphorylated Stat5. To overcome these obstacles, we examined ubiquitination of Stat5AY-F 694 , a Stat5A mutant with the Tyr-694 mutated to Phe. Flag-tagged Stat5AY-F 694 (Stat5AY-F 694 FL) was co-expressed with Jak2 kinase in the presence or absence of wild-type Stat5A in COS-7 cells. As expected,
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Stat5AY-F 694 FL could not be tyrosine-phosphorylated by Jak2 with or without coexpression of wild-type Stat5A ( Figure 7A, upper) . However, in the presence, but not absence, of wild-type Stat5A, Stat5AY-F 694 FL could form heterodimer with tyrosinephosphorylated wild-type Stat5A and be pulled down by the biotin-labeled doublestranded Stat5-binding oligodeoxynucleotides ( Figure 7A, lower) . As a control, Flagtagged wild-type Stat5A (Stat5AFL) could be tyrosine-phosphorylated by Jak2 and pulled down by the Stat5-binding oligodeoxynucleotides ( Figure 7A) . Surprisingly, Stat5AY-F 694 FL pulled down by the Stat5-binding oligodeoxynucleotides was able to be ubiquitinated in vitro, similar to tyrosine-phosphorylated Stat5AFL ( Figure 7B ). These results demonstrate that phosphorylation is not required for ubiquitionation per se, although it is essential for Stat5 dimerization, nucleus translocation and DNA binding. 
, Ubc5b, the reaction mixtures were subjected to Western blot analysis with anti-Flag antibodies. The tyrosine-phosphorylated Stat5A proteins with deletions to amino acids 773 or 762 were able to be ubiquitinated in the cell-free ubiquitination system comparable to the tyrosine-phosphorylated full-length wild-type Stat5A protein ( Figure   7D ). However, the tyrosine-phosphorylated Stat5A proteins with deletions to amino acid 751 or 740 failed to be ubiquitinated ( Figure 7D ). These results demonstrate that the predicted amphipathic alpha-helical region between residues 751-762 41, 42 with no lysine residue directs the ubiquitination of Stat5A. Therefore, these findings provide a mechanism for how this region controls the stability of tyrosine-phosphorylated Stat5A, a phenomenon observed in previous studies. 20 
Discussion
In the present studies, we have discovered different mechanisms for down-regulation of active Stat5A in the nucleus vs. cytoplasm. In the nucleus, proteasome-mediated protein degradation is the dominant mechanism, evidenced by disappearance of nuclear Stat5A protein with time after cytokine withdrawal, stabilization of nuclear active Stat5A by proteasome inhibitor MG132 but not nuclear export inhibitor LMB, and detection of ubiquitinated nuclear active Stat5A. In addition, poly-ubiquitination of tyrosinephosphorylated Stat5A is via a K48-linkage, a type targeting proteins for degradation, and can be recapitulated in a cell-free system. Moreover, we have identified Ubc5 as the E2 for Stat5A ubiquitination and the potential amphipathic alpha-helical region between amino acid residues 751 and 762 within the Stat5A C-terminal domain as a ubiquitination signal that controls Stat5A ubiquitination. 20 Up till the present studies, there have been no direct evidences to support protein degradation as the mechanism for the down-regulation of active Stat5A. One of the reasons might be that previous studies analyze the down-regulation of total active Stat5A in the whole cell lysates which include both nuclear and cytoplasmic Stat5A. 20 In fact, the down-regulation of cytoplasmic active Stat5A is mainly via Shp-2-mediated dephosphorylation. The ubiquitin-proteasome system exists in both the cytoplasm and the nucleus. 43 Precedence for nuclear proteasome-mediated down-regulation of several other transcription factors, including Smad2, MyoD, and the dioxin receptor has been established. [44] [45] [46] These transcription factors are ubiquitinated and degraded in the nucleus. are ubiquitinated in the nucleus but are exported to the cytoplasm for degradation by the ubiquitin-proteasome system. The lack of an effect of the nuclear export inhibitor LMB on the turnover of the nuclear active Stat5A clearly demonstrates that Stat5A is ubiquitinated and degraded in the nucleus without cytoplasmic export, thereby adding Stat5A to the list of transcription factors that undergo proteasomemediated degradation in the nucleus. However, the partial stabilization of cytoplasmic active Stat5A by MG132 suggests that some portion of the cytoplasmic active Stat5A is also down-regulated via proteasome-mediated protein degradation, although it is difficult to detect ubiquitinated-Stat5A in cytoplasm.
The E3 ligases determine the substrate specificity for target proteins via an E3 recognition motif, a trans-acting element on target proteins specifically interacting with its cognate E3 ligase. 37, 39 The finding that tyrosine-phosphorylated Stat5A proteins with deletion to amino acid 762, but not to amino acid 751, were able to be ubiquitinated demonstrates that the small region between amino acids 751 and 762 is involved in the ubiquitination of Stat5A. Noteworthy, the entire carboxy terminal domain of Stat5A, from amino acids 701 to 794, has no lysine residues, the canonical site for ubiquitination.
Thus, this small region cannot be ubiquitinated per se, but likely interacts in trans with a putative Stat5A specific E3 ligase and functions as an E3 recognition motif to direct Stat5A ubiquitination. It is well known that E3 ligase recognition motif can be distant from sites of ubiquitination. 37, 39 The exact ubiquitination site(s) of Stat5A has yet to be determined; however, there are a number of lysine residues distantly upstream of the small region. The pulled down Stat5 proteins from (A) were incubated with human E1, an E2 as indicated, and non-radioactive ubiquitin. Subsequently, the reaction products were subjected to SDS-PAGE, followed by Western blot analyses with anti-ubiquitin ( -Ub) or anti-Stat5A ( -Stat5A) antibodies. 
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